Novo Nordisk A/s

Morten Schlein

Jesper F Lau

Dorte Bjerre Steensgaard

Svend Havelund

Svend Ludvigsen

Helle Naver

Holger Martin Strauss

Peter Madsen

Thomas Kruse Hansen

Dorthe Kot Engelund

Mathias Norrman

Susanne Hostrup

Claude Bonde

Rosa Rebecca Erritzoee Hansen

Jesper Soendergaard Pedersen

Tine Elisabeth Gottschalk Bøving

Lars Bohn Hansen

Thomas Børglum Kjeldsen

Helle Birk Olsen

Liselotte Bjerre Knudsen

Kristian Tage Hansen

Asser Sloth Andersen

Jeppe Sturis

Christian Poulsen

Ulla Ribel-Madsen

Ingrid Petterson

Bjarne Rønfeldt Nielsen

Jens Kaalby Thomsen

Anne Plum

Anne Sofie Kajær Markussen

Anders Robert Sørensen

Anne-Mette Lilleøre

Ejvind Jensen

Tine Elisabeth Gottschalk BØVING

Rosa Rebecca Erritzøe Hansen

Jesper Søndergaard Pedersen

Anne Sofie Kjær Marcussen

Ingrid Vivika Petterson

Ulla Ribel

Anne Sofie Kjær Markussen

Lars Hansen

Tine Elisabeth Gottschalk Boving

The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.

Insulin containing pharmaceutical compositions

The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analog, and to the medical use of such compositions for basal insulin administration therapy.

A stable pharmaceutical formulation containing an insulin derivative can conveniently be prepared by adding glycerol, phenol, m-cresol and zinc ions to it.

Insulin formulations

Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules.

Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide

The present invention is related to single-chain insulin having insulin activity comprising a B- and an A-chain or a modified B- and A-chain connected by a connecting peptide of from 6-11 amino acids. The single-chain insulins will have biological insulin activity and an IGF-1 receptor affinity similar to or lower than that of human insulin and a high physical stability. The single-chain insulin may contain at least one basic amino acid residues in the connecting peptide. The single-chain insulins may also be acylated in one or more Lys residues.

Single-chain insulin

Stable pharmaceutical composition comprising insulinotropic peptide.

Stable formulations of peptides

The invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide and an anionic surfactant, and methods for treatment of hyperglycemia.

Stable formulations of amylin and its analogues

Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.

Preparation comprising insulin, nicotinamide and an amino acid

Pharmaceutical composition for parenteral administration comprising a meal related insulin peptide and an insulinotropic peptide.

Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia

Growing community of inventors

Vaerloese, Denmark

Morten Schlein